"Not So Different": The Biosimilars Forum Wants to Save the Healthcare System Billions

July 7, 2019

Industry group the Biosimilars Forum recently put forth 3 policy proposals that it says could save the US healthcare system billions of dollars. This week on the podcast, we’ve invited the forum to tell us more about its proposals and other policy issues related to biosimilars.

Industry group the Biosimilars Forum recently put forth 3 policy proposals that it says could save the US healthcare system billions of dollars. The group commissioned a scoring analysis from Avalere Health, which found that these options could cut out-of-pocket costs and federal spending by $1.9 billion to $5.2 billion by 2029. This week on the podcast, we’ve invited the forum to tell us more about its proposals and other policy issues related to biosimilars. Joining us this week are Juliana Reed and Molly Burich. Reed is the vice president of corporate affairs, global biosimilars lead at Pfizer, and is also president of the forum. Burich is director of public policy, biosimilars, and reimbursement at Boehringer Ingelheim, and an officer in the forum.

Read more about the forum’s proposals here and here.